Eli Lilly’s Next-Gen Obesity Drug Shows Promising Trial Results in Race Beyond Ozempic

The global obesity drug race is heating up after Eli Lilly and Company announced strong late-stage clinical trial results for its experimental weight loss drug retatrutide. The next-generation obesity treatment delivered significant weight loss in patients with obesity, raising hopes that it could outperform current blockbuster GLP-1 medications such as Ozempic, Wegovy, and Zepbound. According to the Phase 3 trial involving around 2,500 patients, people taking the highest dose of Retatrutide lost an average of 28.3 per cent of their body weight, approximately 70 pounds, over 80 weeks. In comparison, patients receiving a placebo lost only 2.2 per cent of their weight. Health experts say these results are among the strongest ever reported for a weight loss medication.

Nearly 45 per cent of participants achieved at least 30 per cent weight loss, a figure previously associated mostly with bariatric surgery rather than medicines.Also read: Young Student Becomes Delhi’s First Reported Heatstroke Case in Season After Body Temperature Crosses 105°F

What makes Retatrutide different?

Retatrutide is being called a “triple G” obesity drug because it targets three different gut hormones involved in appetite, metabolism, and blood sugar regulation: GLP-1, GIP, and glucagon. Current drugs like Wegovy mainly target GLP-1, while Zepbound targets GLP-1 and GIP. Researchers believe Retatrutide’s three-pronged approach may explain its stronger effects on appetite suppression and calorie burning. Obesity specialists say the findings could represent a major advancement in obesity treatment, especially for patients with severe obesity, diabetes risk, or cardiovascular complications. The trial also showed that around 65 per cent of patients taking the highest dose reached a body mass index (BMI) below 30, moving them out of the obesity category.

Lower dose shows better tolerability

Interestingly, Lilly also tested a lower 4-milligram dose of retatrutide. Patients on this dose lost around 19 per cent of their body weight, still comparable to many currently approved obesity drugs, but experienced fewer side effects. Experts say this may be important because gastrointestinal symptoms remain one of the biggest concerns with GLP-1-based medications. Common side effects reported in the study included nausea, diarrhea, constipation, and abdominal discomfort. At the highest dose, about 42 per cent of patients experienced nausea, while more than 32 per cent reported diarrhoea. Some participants also experienced urinary tract infections and mild nerve-related sensations known as dysesthesia. However, Lilly stated that no major cardiac or liver safety issues were observed during the trial.

The growing global obesity drug market

The success of Retatrutide comes as the global market for obesity and diabetes drugs continues to expand rapidly. Analysts estimate the sector could exceed $100 billion in value by the 2030s. Lilly currently leads much of the obesity drug market with Zepbound, while rival Novo Nordisk dominates with Ozempic and Wegovy. Experts believe Retatrutide could become one of the next major breakthroughs in obesity medicine if approved by regulators. Researchers also say the drug highlights how obesity is increasingly being treated as a chronic metabolic disease rather than simply a lifestyle issue. While the medication still awaits regulatory approval, the latest trial results suggest the future of weight loss treatment may soon move beyond today’s GLP-1 therapies.